Shanxi C&Y Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate
Shanxi C&Y Pharmaceutical Group Co Ltd cash flow reinvestment rate. Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has a Cash Flow Reinvestment Rate of 0.20x as of September 2025, reinvesting CN¥10.37 Million (capex CN¥10.37 Million ) from operating cash flow of CN¥52.93 Million. Explore 300254 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Shanxi C&Y Pharmaceutical Group Co Ltd (2009–2025)
Cash flow reinvestment rate of Shanxi C&Y Pharmaceutical Group Co Ltd from 2009 to 2025. Historical reinvestment intensity for Shanxi C&Y Pharmaceutical Group Co Ltd across 16 annual periods. Explore Shanxi C&Y Pharmaceutical Group Co Ltd capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Shanxi C&Y Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate by Year (2009–2025)
Shanxi C&Y Pharmaceutical Group Co Ltd cash flow reinvestment rate by year from 2009 to 2025. Year-by-year capital reinvestment analysis for Shanxi C&Y Pharmaceutical Group Co Ltd. For the full cash flow conversion analysis, see Shanxi C&Y Pharmaceutical Group Co Ltd cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.95x | CN¥92.24 Million | CN¥96.77 Million | CN¥34.32 Million | ▼ -73.1% |
| 2024 | 3.55x | CN¥251.51 Million | CN¥70.94 Million | CN¥51.50 Million | ▲ +242.9% |
| 2023 | 1.03x | CN¥39.10 Million | CN¥37.81 Million | CN¥33.92 Million | ▲ +54.9% |
| 2022 | 0.67x | CN¥49.98 Million | CN¥74.88 Million | CN¥26.78 Million | ▲ +52.2% |
| 2021 | 0.44x | CN¥42.50 Million | CN¥96.92 Million | CN¥36.93 Million | ▼ -91.4% |
| 2019 | 5.07x | CN¥353.02 Million | CN¥69.63 Million | CN¥18.54 Million | ▼ -46.5% |
| 2018 | 9.47x | CN¥364.07 Million | CN¥38.44 Million | CN¥29.59 Million | ▲ +172.7% |
| 2017 | 3.47x | CN¥139.29 Million | CN¥40.10 Million | CN¥101.07 Million | ▼ -30.0% |
| 2016 | 4.96x | CN¥206.54 Million | CN¥41.65 Million | CN¥50.78 Million | ▼ -60.7% |
| 2015 | 12.61x | CN¥194.77 Million | CN¥15.44 Million | CN¥35.68 Million | ▲ +2931.1% |
| 2014 | 0.42x | CN¥34.20 Million | CN¥82.19 Million | CN¥34.20 Million | ▼ -42.1% |
| 2013 | 0.72x | CN¥57.91 Million | CN¥80.58 Million | CN¥57.91 Million | ▼ -44.5% |
| 2012 | 1.29x | CN¥45.38 Million | CN¥35.05 Million | CN¥45.38 Million | ▼ -90.7% |
| 2011 | 13.90x | CN¥66.03 Million | CN¥4.75 Million | CN¥66.03 Million | ▲ +1414.0% |
| 2010 | 0.92x | CN¥47.78 Million | CN¥52.03 Million | CN¥47.78 Million | ▲ +686.3% |
| 2009 | 0.12x | CN¥12.33 Million | CN¥105.55 Million | CN¥12.33 Million | — |